Review Article

Pathological Importance of the Endothelin-1/ET_B Receptor System on Vascular Diseases

Kento Kitada, Mamoru Ohkita, and Yasuo Matsumura

1 Laboratory of Pathological and Molecular Pharmacology, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka 569-1094, Japan
2 Department of Pharmacology, Kagawa University, Kita-gun, Kagawa 760-0016, Japan

Correspondence should be addressed to Yasuo Matsumura, ymatsumura@gly.oups.ac.jp

Received 10 May 2012; Accepted 27 June 2012

Academic Editor: Theofilos M. Kolettis

Copyright © 2012 Kento Kitada et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Activation of the endothelin (ET)-1/ET receptor system is involved in the development of vascular diseases such as atherosclerosis, vascular hypertrophy, and restenosis. Some issues still remain unresolved including whether ET receptor antagonists are expected to become the new therapeutic tools for the treatment of vascular diseases. One of the unresolved critical points is the functional role of ET receptor subtypes on each vascular disease, in particular the pathophysiological roles of the ET_B receptor. We recently demonstrated that selective inhibition of the ET_B receptor system showed harmful effects in the development of neointimal formation after vascular injury. However, there was no apparent difference in the therapeutic effects between a nonselective ETA/ETB receptor antagonist and selective ET_A receptor antagonist. These findings indicate that antagonism of the ET_A receptor system is essential for suppressing vascular remodeling, irrespective of the presence of ET_B-receptor-mediated actions, although the selective ET_B receptor antagonist worsens vascular remodeling. In addition, we found that ET receptor systems contribute to sex differences in the severity of vascular disease, thereby suggesting that the efficacy of ET receptor antagonists for vascular diseases may differ between sexes. In this paper, we outline the roles of the ET-1/ET_B receptor system on vascular diseases and its sex differences.

1. Introduction

Endothelin (ET)-1 was discovered as a potent and long-lasting vasoconstrictive peptide derived from endothelial cells [1]. ET-1 induces various actions to vessels such as vasoconstriction, vasodilation, and vascular cell proliferation via ET_A and ET_B receptors [2–4]. From previous clinical and basic studies, it has been reported that the ET-1/ET receptor system is one of the critical factors for the development of hypertension and cardiovascular diseases [2–4]. Pathological activation of the ET-1/ET receptor system could play important roles in the development of hypertension, pulmonary hypertension, vascular remodeling (arteriosclerosis and restenosis), myocardial infarction, heart failure, and renal failure [2–4]. A number of studies have been trying to develop an ET receptor antagonist or ET-1 synthesis inhibitor as a new therapeutic tool for hypertension and cardiovascular diseases. So far, an ET_A/ET_B dual receptor antagonist and selective ET_A receptor antagonist have been used as therapeutic agents of pulmonary hypertension. Although there is increasing evidence regarding the cardioprotective and vasoprotective effects of ET receptor antagonists, several issues still remain to be resolved, that is, the pathophysiological roles of ET receptor subtypes (especially the ET_B receptor) in each disease have not been fully elucidated yet. It is one of the critical points for clinical application as to which type of ET receptor antagonist is a better medicine for the treatment of each disease.

2. Vascular ET-1/ET Receptor System in a Physiological State

Vascular endothelial cells mainly produce and secrete ET-1 in vessels. Briefly, big ET-1 is formed from the precursor preproET-1 and mature ET-1 is then produced by endothelin-converting enzyme (ECE). One of the essential
actions of ET-1 is a potent and long-lasting vasoconstrictive effect in vascular smooth muscle cells (VSMCs). Thus, ET-1 blockers have attracted attention as an antihypertensive drug. Along with its strong vasoconstrictive action, ET-1 has a cellular proliferative action in VSMCs [5]. ET-1 causes these vascular effects via ETA and ETB receptors. Both ETA and ETB receptors are located on VSMCs and induce vasoconstriction and cell proliferation. ETB receptors are also expressed on endothelial cells as well as VSMCs. Endothelial ETB receptor mediates vasodilative and antiproliferative actions at least partly via NO production in contrast to its function in VSMCs [6]. Thus, ETB receptors have two kinds of actions in the physiological regulation of vasculature. In addition, the ETB receptor is also well known as a clearance receptor of ET-1 from the circulation [7]. In fact, selective ETB receptor antagonist-treated and ETB-deficient rats exhibited increases in plasma ET-1 levels [8, 9].

3. Vascular ET-1/ET Receptor System in a Pathological State

It has been reported that ET-1 contributes to the development of vascular diseases by having a local effect in addition to its systemic hypertensive effects [2–4, 10, 11]. There are various mechanisms underlying ET-1-induced vascular disorders, such as the induction of inflammation and oxidative stress, increases in growth factors (PDGF, FGF) and proliferative factors (EGF), and production of collagen and extracellular matrix [2–4, 10, 11]. One of the key factors regarding vascular diseases is ET-1-mediated VSMCs proliferation. In fact, clinical and basic studies have indicated that proliferation of VSMCs and neointimal formation in response to ET-1 stimulation play a key role in several vascular lesions such as atherosclerosis, restenosis, and arterial hypertrophy by hypertension or diabetes [10, 11].

There is basic and clinical evidence that has shown activation of the ET-1/ET receptor system in vascular remodeling sites and development of vascular remodeling. In animal model studies, it was reported that an injured artery after balloon injury exhibited increases in mRNA levels of ET-1, ECE, ETA, and ETB receptors [12]. Moreover, continuous ET-1 infusion aggravated neointimal formation after balloon injury [13]. These studies indicate that activation of the ET-1/ET receptor system is involved in the development of vascular remodeling after vascular injury. Actually, a selective ETA receptor and ETB/ET receptor dual receptor antagonist show vasoprotective effects via inhibition of neointimal formation after balloon injury [9, 13–15]. In a clinical study, it was reported that ET-1 levels in the coronary circulation were increased after percutaneous transluminal coronary angioplasty (PTCA) [16]. Furthermore, Shirai et al. [17] reported that neointimal VSMCs after PTCA exhibited enhanced expressions of ECE, ET-1, and ET receptors. This basic and clinical evidence suggests that the ET-1/ET receptor system contributes to the pathogenesis of neointimal formation after vascular injury. Thus, ET receptor antagonists may be useful for the prevention of restenosis after PTCA.

It has been reported that pathological activation of the ET-1/ET receptor system is involved in not only vascular remodeling but also arteriosclerosis. In the arteriosclerotic site of animal models and human patients, ET-1 and its receptor expressions are known to be upregulated [18–20]. Furthermore, ET receptor antagonists could suppress the development of arteriosclerosis in animal models such as LDL receptor- and ApoE-knockout mice [21, 22]. These reports indicated that ET receptor antagonists hold promise for treating arteriosclerosis. Moreover, other papers reported that ET receptor antagonists also suppressed the development of hypertension- and diabetes-induced vascular hypertrophy [23, 24]. These findings suggest that the ET-1/ET receptor system plays an important role in various vascular diseases and that an ET receptor antagonist has vasoprotective effects in the development of various vascular diseases.

For the treatment of vascular diseases with ET antagonists, which type of ET antagonist is the better choice? There is general agreement that the ET-1/ET receptor system plays an important role in the development of vascular disease because ETA receptor-mediated ET-1 actions induce VSMCs proliferation and both selective ETA receptor and ETB/ET receptor dual receptor antagonists showed vasoprotective effects. However, the pathological role of the ET-1/ETB receptor system on vascular diseases has not been fully elucidated because of the opposite effects of endothelial and VSMC ETB receptor-mediated actions (Figure 1(a)). Therefore, it is still difficult to answer which type of ET antagonist is more effective for the treatment of vascular disease.

4. Pathophysiological Roles of the ETB Receptor in Vascular Diseases

To identify the functional influences of the ETB receptor on vascular diseases, we investigated the effects of ETB receptor blockade at pharmacological or genetic levels on the development of neointimal formation after balloon injury. We clearly demonstrated that inhibition of the ETB receptor system, using a selective ETB receptor antagonist or ETB-deficient rat, aggravated neointimal formation after balloon injury [9]. These results led us to propose that the ET-1/ETB receptor system is protective in the pathogenesis of neointimal formation after balloon injury and that a selective ETA receptor antagonist may be more effective than a nonselective ETA/ETB receptor antagonist for the prevention of neointimal formation. Interestingly, an ETA/ETB dual receptor antagonist as well as a selective ETA receptor antagonist markedly suppressed the development of neointimal formation, and the efficacy of treatment was comparable between the above two types of antagonists [9]. Furthermore, aggravated neointimal formation observed in ETB-deficient rats was dramatically improved by the inhibition of the ETA receptor [9], suggesting that aggravated neointimal formation after balloon injury in the ETB receptor-inhibited condition can be prevented by pharmacological blockade of ETA receptors. In addition, antagonism of the ETB receptor itself does not seem to impair the positive effects of
**Figure 1:** Roles of the ET-1/ET receptor system on vascular injury. (a) The vascular effects of ET-1 are mediated by ET\(_A\) and ET\(_B\) receptors. ET\(_A\)-mediated ET-1 action has been considered to cause vascular injury. ET\(_B\) receptors are expressed not only on vascular smooth muscle cells, but also on endothelial cells. In addition, the ET\(_B\) receptor is a clearance receptor of ET-1 from the circulation. However, the roles of the ET\(_B\) receptor on vascular injury are still controversial. Recently, it was reported that nonendothelial ET\(_B\)-receptor induced vasoprotective effects, whereas another previous study demonstrated that ET\(_B\)-receptor-mediated ET-1 action exhibited vasoprotective effects via NO production [25, 26]. (b) Inhibition of the ET\(_B\) receptor system leads to an aggravation of vascular injury. Increased circulating ET-1 levels because of clearance receptor inhibition and the augmentation of ET\(_A\)-mediated actions are mainly responsible for aggravated vascular injury in the ET\(_B\) receptor-inhibited condition [9]. ET, endothelin; NO, nitric oxide; eNOS; endothelial nitric oxide synthesis; L-Arg. L-Arginine.

Concomitant ET\(_A\) receptor antagonism. These findings may lead us to propose an important conclusion where chronic inhibition of ET\(_B\) receptors leads to an overstimulation and/or upregulation of the ET\(_A\) receptor system; therefore, it seems likely that an augmentation in ET\(_A\) receptor-mediated ET-1 actions is an essential factor for the enhancement of neointimal formation observed in ET\(_B\) receptor antagonist-treated and ET\(_B\)-deficient rats rather than blockade of the ET\(_B\) receptor-mediated vasoprotective effect (Figure 1(b)). In other words, antagonism of the ET\(_A\) receptor is essential for the inhibition of neointimal formation after balloon injury, irrespective of the presence of ET\(_B\) receptor-mediated actions. This hypothesis could explain why both selective ET\(_A\) receptor and nonselective ET\(_A/ET\(_B\) dual receptor antagonists are equally effective in suppressing neointimal formation [9, 13–15].
Other disease models such as hypertension and pulmonary hypertension, as well as the balloon injury model, showed overactivation of the ET$_A$ receptor system in the ET$_B$ receptor-inhibited condition, but the detailed mechanism has not been fully elucidated yet [9, 24, 27, 28]. One possible factor is an increase in plasma ET-1 concentrations in the ET$_B$ receptor-inhibited condition because ET$_B$ receptors work as a clearance receptor of ET-1 from the circulation (Figure 1(b)) [7–9]. Further research is required to explain why ET$_A$ receptor action is augmented in the ET$_B$-inhibited condition.

As described above, we demonstrated that selective inhibition of the ET$_B$ receptor induces a harmful effect in the balloon injury model. Murakoshi et al. [25] also reported that vascular remodeling caused by a vascular ligation model was markedly enhanced in ET$_B$-receptor-knockout mice or selective ET$_B$ receptor antagonist-treated mice, whereas selective ET$_A$ receptor blockade suppressed this vascular remodeling in mice. Furthermore, Sachidanandam et al. [29, 30] found that resistance artery remodeling in diabetic rats was aggravated by a selective ET$_B$ receptor antagonist, in contrast to the beneficial effects of a selective ET$_A$ receptor antagonist and ET$_A$/ET$_B$ receptor antagonist. Taken together, selective inhibition of ET$_B$ receptors causes harmful effects in several vascular disease models. However, it is unclear whether ET$_B$ receptor-mediated vasoprotective actions are directly responsible for aggravated vascular diseases in the ET$_B$ receptor-inhibited condition, and whether a selective ET$_A$ receptor antagonist is more effective than an ET$_A$/ET$_B$ receptor antagonist. In the case of a ligation-induced vascular remodeling model, the efficacy of a selective ET$_A$ receptor antagonist is more in wild-type mice than in ET$_B$-knockout mice [25], suggesting that the ET$_B$ receptor system itself exerts an aggressive vasoprotective effect on vascular disease, in contrast to our findings obtained using a balloon injury model [9]. Why are the roles of the ET$_B$ receptor different between ligation- and balloon injury-induced vascular injury models? One of the possible answers is differences between vascular injury models. The balloon injury model causes endothelial injury, therefore, there are no endothelial cells in the injured artery site after balloon injury. Meanwhile, endothelial ET$_B$ receptor stimulation in a vascular ligation model can mediate NO production and anti-proliferative action because vascular endothelial cells exist in this model. Actually, it was reported that tissue NOX levels are lower in the injured artery site of ET$_B$-knockout mice than that of wild-type mice [25]. Therefore, vascular remodeling models that have endothelial cells may indicate active vasoprotective effects of the ET$_B$ receptor in contrast to the endothelium-injury model.

However, recent evidence does not support the above view. Kirkby et al. [26] demonstrated that nonendothelial cell ET$_B$ receptors could limit the development of neointimal formation after wire injury using endothelial cell-specific ET$_B$ knockout mice. That is, selective deletion of ET$_B$ receptors from the endothelium had no effect on neointimal formation after vascular injury whereas a selective ET$_B$ receptor antagonist aggravated neointimal formation after vascular injury in mice [26]. Furthermore, they showed that a selective ET$_B$ receptor antagonist reversed the vasoprotective effects of a selective ET$_A$ receptor antagonist in the same model [26]. These findings indicate that nonendothelial ET$_B$ receptors have aggressive vasoprotective effects and that selective ET$_A$ receptor antagonists are preferable to ET$_A$/ET$_B$ receptor antagonists for the treatment of vascular injury. Therefore, their observations regarding the vasoprotective effects of ET$_B$ receptors are completely different from our results. At present, we cannot explain why these differences in ET$_B$ receptor function occurred in each model. Further efforts to elucidate the roles of both endothelial and nonendothelial ET$_B$ receptors are needed in future studies.

There are still some important questions regarding ET$_B$ receptors in vascular diseases. However, the same findings from previous studies are that selective inhibition of the ET$_B$ receptor system aggravates vascular remodeling in contrast to the beneficial effects of ET$_A$ receptor blockade. Therefore, a selective ET$_A$ receptor antagonist may be superior to an ET$_A$/ET$_B$ dual receptor antagonist in vascular diseases under existing conditions.

However, it still remains unclear in human patients in the priority of the treatment by an ET$_A$/ET$_B$ dual receptor antagonist or a selective ET$_A$ receptor antagonist in the cardiovascular diseases. This will need the randomized, double-blinded clinical trial in the patients with cardiovascular diseases.

5. ET-1/ET Receptor System and Sex Differences in Vascular Diseases

Epidemiology-based clinical investigations have demonstrated that the incidence of cardiovascular disease is lower in premenopausal women than that of men and postmenopausal women [31, 32]. Although the detailed mechanisms to explain this cardiovascular disease-related sex difference have not been fully elucidated, the vasoprotective effects of estrogen are contributive at least partly to this sex difference [33–35]. It is well known that estrogen has pleiotropic vasoprotective effects via several mechanisms such as upregulation of endothelial NO production and downregulation of adhesion molecule activity, smooth muscle proliferation/migration, and superoxide production [36–38].

On the other hand, it has been indicated that ET-1/ET receptor systems contribute to the sex difference of cardiovascular diseases and hypertension [39, 40]. There is some clinical evidence showing the association between ET-1 and sex differences in the cardiovascular system. Plasma ET-1 concentrations are higher in men than women, and older women show high plasma ET-1 levels [41–43]. Interestingly, plasma ET-1 levels are known to change after sex-change operations [44]. Meanwhile, 17β-estradiol treatment in postmenopausal women decreases plasma ET-1 levels [41]. Basic studies also indicated that estrogen suppressed ET-1 production and its action [39, 45]. These reports suggest that ET-1 systems are closely related to the mechanisms of sex differences in cardiovascular diseases and seem to contribute to the increase in incidence of cardiovascular events in postmenopausal women.
Moreover, there are some reports regarding the possible involvement of ET receptors in the sex differences in vessel function. In human saphenous veins, men exhibit higher total number of ET-1 receptors as well as a higher ratio of ET\textsubscript{A} to ET\textsubscript{B} receptors than those of women [46]. In deoxycorticosterone acetate/salt-induced hypertension rats, vascular mRNA expression of ET\textsubscript{B} receptors is higher in males than that in females [47, 48]. Moreover, it has been reported that endogenous estrogen or exogenous 17β-estradiol treatment regulates ET receptor gene expression in vessels [47, 49]. These clinical and basic studies suggest that changes in ET receptor distribution in the vasculature may play an important role in the mechanism of sex differences of cardiovascular diseases and/or hypertension.

6. Roles of the ET\textsubscript{B} Receptor in the Sex Differences of Vascular Diseases

In animal models of vascular lesions such as neointimal formation after vascular injury, male rats developed a more robust neointimal response to vascular injury than females. Furthermore, neointimal formation in females was augmented by ovariectomy and this augmentation was abolished by 17β-estradiol replacement [50]. Thus, there are clear sex differences about neointimal formation after vascular injury in animal models. The mechanisms underlying this sex difference have not been fully elucidated, but are considered to be at least partly related to the vasoprotective actions of estrogen [50].

We recently found that the function of ET\textsubscript{B} receptors is involved in the sex differences for the development of neointimal formation after balloon injury in rats. In that study, the extent of neointimal formation after balloon injury in wild-type rats was much lower in females than in males [8]. In contrast, in ET\textsubscript{B}-deficient rats, the incidence of neointimal formation after balloon injury was markedly increased to the same extent in males and females [8]. Furthermore, treatment with a selective ET\textsubscript{B} receptor antagonist also abolished the sex differences of balloon injury-induced neointimal formation in rats [8]. These results indicate that sex differences in this vascular lesion were completely abolished in the ET\textsubscript{B} receptor-inhibited condition. Therefore, ET\textsubscript{B} receptors could play an important role in the sex differences observed in the development of balloon injury-induced neointimal formation.

We evaluated the involvement of estrogen-induced vasoprotective effects on this abolition of sex differences. In female wild-type rats, neointimal formation after balloon injury is markedly aggravated by ovariectomy and this aggravation is almost completely reversed by 17β-estradiol treatment, clearly indicating that estrogen inhibits neointimal formation after vascular injury in female wild-type rats [8]. Importantly, ovariectomy and 17β-estradiol treatment failed to affect the neointimal formation observed in female ET\textsubscript{B}-deficient rats [8]. These findings indicate that estrogen is likely to inhibit neointimal formation after vascular injury via a mechanism that is dependent on ET\textsubscript{B} receptor-mediated actions since the vasoprotective effects of estrogen after vascular injury were abolished in ET\textsubscript{B}-deficient rats. Furthermore, ET\textsubscript{B} receptor-mediated actions seem to occur downstream of the vasoprotective effects of estrogen. However, the possibility that marked augmentation of balloon injury-induced neointimal formation by ET\textsubscript{B} receptor deficiency merely induces functional abolition of the above-mentioned sex differences cannot be ruled out. Further investigations are required to clarify the crosstalk between estrogen receptor- and ET\textsubscript{B} receptor-mediated actions. We further examined the possible involvement of ET\textsubscript{A} receptor-mediated actions on the abolition of sex differences of the balloon injury model in ET\textsubscript{B}-deficient rats and found that the aggravation of neointimal formation after balloon injury in female ET\textsubscript{B}-deficient rats was completely suppressed by the blockade of ET\textsubscript{A} receptors [8]. Thus, we suggest that the augmentation of ET\textsubscript{A} receptor-mediated actions rather than ET\textsubscript{B} receptor deficiencies itself contributes to the abolition of the sex differences in ET\textsubscript{B}-deficient rats.

On the other hand, treatment with a selective ET\textsubscript{A} receptor antagonist or ET\textsubscript{A}/ET\textsubscript{B} dual receptor antagonist did not affect neointimal formation after balloon injury in female normal rats, whereas these ET receptor antagonists clearly inhibited neointimal formation in male normal rats [8]. It seems likely that there are sex differences in the vasoprotective effects of ET receptor antagonists and that ET\textsubscript{A}-induced neointimal formation after balloon injury in intact female rats is lower than that observed in male rats.

In clinical fields, several studies showed that postmenopausal women who receive estrogen replacement therapy (ERT) have a substantially lower risk of incidence of cardiovascular disease [51, 52]. However, other clinical trials produced different results. The Heart Estrogen-Progestin Replacement Study (HERS) and Women’s Health Initiative (WHI) clinical trial and observational study did not lead to any benefit of ERT [53, 54]. Thus, the effects of ERT on cardiovascular disease are still controversial, and determinations of the mechanisms of estrogen-exhibited vasoprotective effects and the alternative therapy of estrogen in postmenopausal women remain critical issues. Previous studies by us and others suggest that ET\textsubscript{A} receptor-mediated ET-1 actions may be higher in vascular lesion sites of men and postmenopausal women than those of premenopausal women. Thus, an ET\textsubscript{A} receptor antagonist may become a useful tool for reducing the risk of cardiovascular diseases after menopause.

In summary, we demonstrated that ET\textsubscript{B}-receptor actions are involved in the sex differences of vascular injury model. The lack of vasoprotective effects of estrogen and the augmentation of ET\textsubscript{A} receptor-mediated actions may be responsible for the abolition of these sex differences observed in the ET\textsubscript{B} receptor-inhibited condition. Although more detailed mechanisms underlying the abolition of sex differences remain to be clarified, we found that modulation of ET-1 and ET receptor expressions by estrogen in injured arteries after vascular injury does not seem to contribute to sex differences in the development of neointimal formation [8]. Finally, efficacious treatment with ET receptor antagonists for vascular diseases may differ between sexes. We expect an accumulation of clinical evidence regarding the relationship...
between the vasoprotective effects of ET receptor antagonists and sex differences.

**Acknowledgments**

The authors are grateful to Drs. Masashi Yanagisawa (Howard Hughes Medical Institute and Department of Molecular Genetics, University of Texas South-Western Medical Center, Dallas, TX, USA) and Cheryl E. Gariepy (Center for Cell and Developmental Biology, The Research Institute at The Nationwide Children's Hospital, Pediatric Gastroenterology, Columbus, OH, USA) for supplying ETB-deficient breeder rats. The authors thank Daniel Mrozek for reading the paper.

**References**

[1] M. Yanagisawa, H. Kurihara, S. Kimura et al., “A novel potent vasoconstrictor peptide produced by vascular endothelial cells,” *Nature*, vol. 332, no. 6163, pp. 411–415, 1988.

[2] K. Goto, H. Hama, and Y. Kasuya, “Molecular pharmacology and pathophysiological significance of endothelin,” *Japanese Journal of Pharmacology*, vol. 72, no. 4, pp. 261–290, 1996.

[3] T. Miyauchi and T. Masaki, “Pathophysiology of endothelin in the cardiovascular system,” *Annual Review of Physiology*, vol. 61, pp. 391–415, 1999.

[4] E. Thorin and M. Clozel, “The cardiovascular physiology and pharmacology of endothelin-1,” *Advances in Pharmacology*, vol. 60, pp. 1–26, 2010.

[5] Y. Hirata, Y. Takagi, Y. Fukuda, and F. Marumo, “Endothelin is a potent mitogen for rat vascular smooth muscle cells,” *Atherosclerosis*, vol. 78, no. 2–3, pp. 225–228, 1996.

[6] M. Clozel, G. A. Gray, V. Breu, B. M. Loffler, and R. Osterwalder, “The endothelin ET(B) receptor mediates both vasodilation and vasoconstriction in vivo,” *Biochemical and Biophysical Research Communications*, vol. 186, no. 2, pp. 867–873, 1992.

[7] T. Fukuroda, T. Fujikawa, S. Ozaki, K. Ishikawa, M. Yano, and M. Nishikibe, “Clearance of circulating endothelin-1 by ETB receptors in rats,” *Biochemical and Biophysical Research Communications*, vol. 199, no. 3, pp. 1461–1465, 1994.

[8] K. Kitada, N. Yui, M. Koyama et al., “Endothelin ETB receptor is involved in sex differences in the development of balloon injury-induced neointimal formation,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 336, no. 2, pp. 533–539, 2011.

[9] K. Kitada, N. Yui, C. Matsumoto, T. Mori, M. Ohkita, and Y. Matsumura, “Inhibition of endothelin ETB receptor system aggravates neointimal hyperplasia after balloon injury of rat carotid artery,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 331, no. 3, pp. 998–1004, 2009.

[10] M. Kirchengast and K. Münter, “Endothelin and restenosis,” *Cardiovascular Research*, vol. 39, no. 3, pp. 550–555, 1998.

[11] M. Takahashi, “The role of endothelin-1 in vascular remodeling in vivo,” *Cardiovascular Research*, vol. 71, no. 1, pp. 4–5, 2006.

[12] X. Wang, S. A. Douglas, C. Louden, L. M. Vickery-Clark, G. Z. Feuerstein, and E. H. Olshen, “Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat,” *Circulation Research*, vol. 78, no. 2, pp. 322–328, 1996.

[13] S. A. Douglas, C. Louden, L. M. Vickery-Clark et al., “A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670,” *Circulation Research*, vol. 75, no. 1, pp. 190–197, 1994.

[14] C. J. McKenna, S. E. Burke, T. J. Opgenorth et al., “Selective ET(A) receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model,” *Circulation*, vol. 97, no. 25, pp. 2551–2556, 1998.

[15] M. Sanmartin, A. Fernández-Ortiz, P. Fantidis et al., “Effects of bosentan on neointimal response following coronary angioplasty,” *European Journal of Clinical Investigation*, vol. 33, no. 9, pp. 762–768, 2003.

[16] H. Takase, M. Sugiyama, A. Nakazawa et al., “Increased endogenous endothelin-1 in coronary circulation is associated with restenosis after coronary angioplasty,” *Canadian Journal of Cardiology*, vol. 19, no. 8, pp. 902–906, 2003.

[17] N. Shirai, T. Naruko, M. Ohsawa et al., “Expression of endothelin-converting enzyme, endothelin-1 and endothelin receptors at the site of percutaneous coronary intervention in humans,” *Journal of Hypertension*, vol. 24, no. 4, pp. 711–721, 2006.

[18] S. Iwasa, J. Fan, T. Shimokama, M. Nagata, and T. Watanabe, “Increased immunoreactivity of endothelin-1 and endothelin B receptor in human atherosclerotic lesions. A possible role in atherogenesis,” *Atherosclerosis*, vol. 146, no. 1, pp. 93–100, 1999.

[19] T. Kobayashi, T. Miyauchi, S. Iwasa et al., “Corresponding distributions of increased endothelin-B receptor expression and increased endothelin-1 expression in the aorta of apolipoprotein E-deficient mice with advanced atherosclerosis,” *Pathology International*, vol. 50, no. 12, pp. 929–936, 2000.

[20] A. Lerman, M. W. I. Webster, J. H. Chesbro et al., “Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs,” *Circulation*, vol. 88, no. 6, pp. 2923–2928, 1993.

[21] S. Babaei, P. Picard, A. Ravandi et al., “Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation,” *Cardiovascular Research*, vol. 48, no. 1, pp. 158–167, 2000.

[22] M. Barton, C. C. Haudenschild, L. V. D’Uscio, S. Shaw, K. Münter, and T. E. Lüscher, “Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 24, pp. 14367–14372, 1998.

[23] G. Fukuda, Z. A. Khan, Y. P. Barbin, H. Farhangkhoee, R. G. Tilton, and S. Chakrabarti, “Endothelin-mediated remodeling in aortas of diabetic rats,” *Diabetes/Metabolism Research and Reviews*, vol. 21, no. 4, pp. 367–375, 2005.

[24] Y. Matsumura, T. Kuro, Y. Kobayashi et al., “Exaggerated vascular and renal pathology in endothelin-B receptor-deficient rats with deoxycorticosterone acetate-salt hypertension,” *Circulation*, vol. 102, no. 22, pp. 2765–2773, 2000.

[25] N. Murakoshi, T. Miyauchi, Y. Kakinuma et al., “Vascular endothelin-B receptor system in vivo plays a favorable inhibitory role in vascular remodeling after injury revealed by endothelin-B receptor-knockout mice,” *Circulation*, vol. 106, no. 15, pp. 1991–1998, 2002.

[26] N. S. Kirkby, K. M. Duthie, E. Miller et al., “Non-endothelial cell endothelin-B receptors limit neointima formation following vascular injury,” *Cardiovascular Research*, vol. 95, no. 1, pp. 19–28, 2012.
[27] M. Nishida, K. Eshiro, Y. Okada, M. Takaoka, and Y. Matsumura, “Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension,” Journal of Cardiovascular Pharmacology, vol. 44, no. 2, pp. 187–191, 2004.

[28] M. Nishida, Y. Okada, K. Akiyoshi et al., “Role of endothelin ETB receptor in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats,” European Journal of Pharmacology, vol. 496, no. 1-3, pp. 159–165, 2004.

[29] K. Sachidanandam, V. Portik-Dobos, A. K. Harris et al., “Evidence for vasculoprotective effects of ETB receptors in resistance artery remodeling in diabetes,” Diabetologia, vol. 56, no. 11, pp. 2733–2738, 2007.

[30] K. Sachidanandam, V. Portik-Dobos, A. I. Kelly-Cobbs, and A. Ergul, “Dual endothelin receptor antagonism prevents remodeling of resistance arteries in diabetes,” Canadian Journal of Physiology and Pharmacology, vol. 88, no. 6, pp. 616–621, 2010.

[31] T. L. Bush and E. Barrett-Connor, “Noncontraceptive estrogen effects and outstanding questions,” American Heart Journal, vol. 114, no. 1-2, pp. 85–103, 1987.

[32] I. F. Godsland, V. Wynn, D. Crook, and N. E. Miller, “Sex, plasma lipoproteins, and atherosclerosis: prevailing assumptions and outstanding questions,” American Heart Journal, vol. 114, no. 6, pp. 1467–1503, 1987.

[33] M. Y. Farhat, M. C. Lavigne, and P. W. Ramwell, “The vascular protective effects of estrogen,” The FASEB Journal, vol. 10, no. 5, pp. 615–624, 1996.

[34] M. E. Mendelsohn and R. H. Karas, “The protective effects of estrogen on the cardiovascular system,” The New England Journal of Medicine, vol. 340, no. 23, pp. 1801–1811, 1999.

[35] M. J. Stampfer, G. A. Colditz, W. C. Willett et al., “Postmenopausal estrogen therapy and cardiovascular disease—ten-year follow-up from the Nurses’ Health Study,” The New England Journal of Medicine, vol. 325, no. 11, pp. 756–762, 1991.

[36] M. Florian, A. Freiman, and S. Magder, “Treatment with 17β-estradiol reduces superoxide production in aorta of ovariectomized rats,” Steroids, vol. 69, no. 13-14, pp. 779–787, 2004.

[37] A. P. Miller, Y. F. Chen, D. Xing, W. Feng, and S. Oparil, “Hormone replacement therapy and inflammation: interactions in cardiovascular disease,” Hypertension, vol. 42, no. 4, pp. 657–663, 2003.

[38] T. Tolbert, J. A. Thompson, P. Bouchard, and S. Oparil, “Estrogen-induced vasoprotection is independent of inducible nitric oxide synthase expression: evidence from the mouse carotid artery ligation model,” Circulation, vol. 104, no. 22, pp. 2740–2745, 2001.

[39] R. C. Tostes, Z. B. Fortes, G. E. Callera et al., “Endothelin, sex and hypertension,” Clinical Science, vol. 114, no. 1-2, pp. 85–97, 2008.

[40] H. Kawanishi, Y. Hasegawa, D. Nakano et al., “Involvement of the endothelin ETB receptor in gender differences in deoxycorticosterone acetate-salt-induced hypertension,” Clinical and Experimental Pharmacology and Physiology, vol. 34, no. 4, pp. 280–285, 2007.

[41] P. J. M. Best, P. B. Berger, V. M. Miller, and A. Lerman, “The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women,” Annals of Internal Medicine, vol. 128, no. 4, pp. 285–288, 1998.

[42] S. Maeda, T. Tanabe, T. Miyauchi et al., “Aerobic exercise training reduces plasma endothelin-1 concentration in older women,” Journal of Applied Physiology, vol. 95, no. 1, pp. 336–341, 2003.

[43] T. Miyauchi, M. Yanagisawa, K. Iida et al., “Age- and sex-related variation of plasma endothelin-1 concentration in normal and hypertensive subjects,” American Heart Journal, vol. 123, no. 4, part 1, pp. 1092–1093, 1992.

[44] K. H. Polderman, C. D. Stehouwer, G. J. Van Kamp, G. A. Dekker, F. W. Verheugt, and L. J. Gooren, “Influence of sex hormones on plasma endothelin levels,” Annals of Internal Medicine, vol. 118, no. 6, pp. 429–432, 1993.

[45] O. Lekontseva, S. Chakrabarti, and S. T. Davidge, “Endothelin in the female vasculature: a role in aging?” American Journal of Physiology, vol. 298, no. 3, pp. R509–R516, 2010.

[46] A. Ergul, K. Shoemaker, D. Puett, and R. L. Tackett, “Gender differences in the expression of endothelin receptors in human saphenous veins in vitro,” Journal of Pharmacology and Experimental Therapeutics, vol. 285, no. 2, pp. 511–517, 1998.

[47] F. L. David, M. H. Carvalho, A. L. Cobra et al., “Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats,” Hypertension, vol. 38, no. 3, part 2, pp. 692–696, 2001.

[48] F. L. David, A. C. Montezano, N. A. Rebouças et al., “Gender differences in vascular expression of endothelin and ETA/ETB receptors, but not in calcium handling mechanisms, in deoxycorticosterone acetate-salt hypertension,” Brazilian Journal of Medical and Biological Research, vol. 35, no. 9, pp. 1061–1068, 2002.

[49] S. H. Pedersen, L. B. Nielsen, A. Mortensen, L. Nilas, and B. Ottesen, “Progestins oppose the effects of estradiol on the endothelin-1 receptor type B in coronary arteries from ovariectomized hyperlipidemic rabbits,” Menopause, vol. 15, no. 3, pp. 503–510, 2008.

[50] S. J. Chen, H. Li, J. Durand, S. Oparil, and Y. F. Chen, “Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery,” Circulation, vol. 93, no. 3, pp. 577–584, 1996.

[51] D. Grady, S. M. Rubin, D. B. Petitti et al., “Hormone therapy to prevent disease and prolong life in postmenopausal women,” Annals of Internal Medicine, vol. 117, no. 12, pp. 1016–1037, 1992.

[52] B. W. Walsh, I. Schiff, B. Rosner, L. Greenberg, V. Ravnikar, and F. M. Sacks, “Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins,” The New England Journal of Medicine, vol. 325, no. 17, pp. 1196–1204, 1991.

[53] S. Hulle, D. Grady, T. Bush et al., “Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women,” The Journal of the American Medical Association, vol. 280, no. 7, pp. 605–613, 1998.

[54] J. E. Rossouw, G. L. Anderson, R. L. Prentice et al., “Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial,” The Journal of the American Medical Association, vol. 288, no. 3, pp. 321–333, 2002.